

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/502

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, CHEM ABS Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MESTERS R M ET AL: "ANGIOGENESIS BEI HAEMATOLOGISCHEN NEOPLASIEN" ONKOLOGIE, KARGER, FREIBURG, DE, vol. 24, no. SUPPL 5, 2001, pages 75-80, XP001135111 ISSN: 0378-584X abstract ----	1-15
Y	WO 98 35958 A (NOVARTIS ERFIND VERWALT GMBH ;CIBA GEIGY AG (CH); TRAXLER PETER (C) 20 August 1998 (1998-08-20) cited in the application claims 1-15; examples 1-85 ----	1-15 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

4 February 2004

13/02/2004

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kling, I

INTERNATIONAL SEARCH REPORT

ional Application No

P 03/11084

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WOOD J M: "INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AS A NOVEL APPROACH FOR CANCER THERAPY" MEDICINA, BUENOS AIRES, AR, vol. 60, no. SUPPL 2, 2000, pages 41-47, XP008002456 ISSN: 0025-7680 abstract ---	1-15
Y	WOOD J M ET AL: "PTK787/ZK 222584, A NOVEL AND POTENT INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES, IMPAIRS VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED RESPONSES AND TUMOR GROWTH AFTER ORAL ADMINISTRATION" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 8, 15 April 2000 (2000-04-15), pages 2178-2189, XP000971163 ISSN: 0008-5472 page 2184, right-hand column, last paragraph -page 2187, right-hand column, last paragraph ---	1-15
Y	LIN B K ET AL: "THE VEGF RECEPTOR TYROSINE KINASE INHIBITOR PTK787 INHIBITS PROLIFERATION AND MIGRATION OF MULTIPLE MYELOMA CELLS, AND REDUCES PARACRINE-MEDIATED RESPONSES TO THE BONE MARROW MICROENVIRONMENT" BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 98, no. 11, PART 1, 16 November 2001 (2001-11-16), page 166A XP001135110 ISSN: 0006-4971 abstract ---	1-15
Y	TRAXLER P ET AL: "TYROSINE KINASE INHIBITORS: FROM RATIONAL DESIGN TO CLINICAL TRIALS" MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 21, no. 6, November 2001 (2001-11), pages 499-512, XP009012042 ISSN: 0198-6325 page 505, paragraph 3. -page 507, paragraph 4 ---	1-15
Y	WO 02 41882 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); TRAXLER PETER (CH)) 30 May 2002 (2002-05-30) claims 1-19 ---	1-15
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/11084

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 03 035047 A (NOVARTIS PHARMA GMBH ;NOVARTIS AG (CH); CHEN YING-NAN PAN (US); LA) 1 May 2003 (2003-05-01) claims 1-28 -----	1-15
P,Y	WO 03 022282 A (NOVARTIS PHARMA GMBH ;NOVARTIS AG (CH); WOOD JEANETTE MARJORIE (CH) 20 March 2003 (2003-03-20) claims 1-27 -----	1-15
P,X	WO 03 059354 A (KLUENDER HAROLD C E ;DUMAS JACQUES (US); ADAMS PAUL E (US); BAYER) 24 July 2003 (2003-07-24) page 76, line 1 -page 79, line 22; claims 1-15; example 1; table 1 -----	1-15
P,X	ROBOZ GAIL J ET AL: "Phase I Trial of PTK787/ZK 222584, an Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Acute Myeloid Leukemia and Myelodysplastic Syndrome." BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page Abstract No. 1308 XP009025184 44th Annual Meeting of the American Society of Hematology;Philadelphia, PA, USA; December 06-10, 2002 ISSN: 0006-4971 abstract -----	1-15
A	ESCRIBANO L ET AL: "EXPRESSION OF THE C-KIT (CD117) MOLECULE IN NORMAL AND MALIGNANT HEMATOPOIESIS" LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 30, no. 5/6, 1998, pages 459-466, XP001135035 ISSN: 1042-8194 abstract -----	1-15

INTERNATIONAL SEARCH REPORT

International Application No.

R 03/11084

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9835958	A	20-08-1998		AU 731852 B2 AU 6621898 A BR 9807685 A CN 1251097 T CZ 9902853 A3 WO 9835958 A1 EP 0970070 A1 HU 0001046 A2 ID 23698 A JP 2001508800 T NO 993888 A NZ 337064 A PL 335113 A1 RU 2207132 C2 SK 109699 A3 TR 9901953 T2 US 2003191129 A1 US 6258812 B1 US 2002091261 A1 ZA 9801155 A		05-04-2001 08-09-1998 21-03-2000 19-04-2000 17-11-1999 20-08-1998 12-01-2000 28-04-2001 11-05-2000 03-07-2001 11-10-1999 27-04-2001 10-04-2000 27-06-2003 13-03-2000 21-10-1999 09-10-2003 10-07-2001 11-07-2002 13-08-1998
WO 0241882	A	30-05-2002		AU 2368402 A CA 2427184 A1 WO 0241882 A2 EP 1339458 A2		03-06-2002 30-05-2002 30-05-2002 03-09-2003
WO 03035047	A	01-05-2003		WO 03035047 A2		01-05-2003
WO 03022282	A	20-03-2003		WO 03022282 A1		20-03-2003
WO 03059354	A	24-07-2003		WO 03059354 A2		24-07-2003